Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.
In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.
In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.
Location: Singapore
Employees: 11-50
Total raised: $94M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | 6 Dimensio... | 6dimension... |
| - | Camford Ca... | camford.co... |
| - | MBC BioLab... | mbcbiolabs... |
| - | DHVC | dh.vc |
| - | WI Harper ... | wiharper.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.10.2023 | Series A | $27M | - |
| 03.06.2021 | Series A | $57M | - |
| 31.01.2018 | Seed | $10M | - |
Mentions in press and media 20
| Date | Title | Description |
| 08.04.2025 | Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer | This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development. The partnership will advance the development of first-in-c... |
| 02.11.2023 | Deals in brief: Tabby attains unicorn status, Funding Societies secures USD 7.5 million in debt funding, SPH Media acquires Tech in Asia, and more | Tabby raises USD 200 million, attaining unicorn status The Riyadh-based fintech startup, which offers buy now, pay later services to consumers in the Middle East, has secured USD 200 million in its Series D funding round, propelling its val... |
| 01.11.2023 | Deals in brief: Engine Biosciences extends Series A round, Talino Venture Studios secures investment from Chemonics, ten China deals, and more | Engine Biosciences raises USD 27 million in extension of Series A round The Singapore-based biotech startup has raised an additional USD 27 million, bringing its total funds raised at the Series A level to USD 70 million. Polaris Partners l... |
| 31.10.2023 | Engine Biosciences Raises $27M in Series A Extension | Engine Biosciences, a Singapore- and Redwood City, CA-based company leveraging machine learning and biology to discover and develop precision oncology medicines, raised $27M in Series A extension. The round, which brought the total amount t... |
| 03.10.2023 | Singapore biotech firm Engine Biosciences raises $5m more in latest round | Engine Biosciences, a Singapore- and Silicon Valley-based biotech company, has raised $5 million more in its Series A-3 funding round, according to its recent filings. |
| 03.10.2023 | Deals in brief: MADCash bags MYR 5 million, Visa jumps on generative AI bandwagon, Bain Capital leads investment in Vietnam’s Masan Group, and more | MADCash secures MYR 5 million in pre-Series A funding round led by Artem Ventures The Kuala Lumpur-based fintech solutions provider has secured MYR 5 million (USD 1.05 million) in a pre-Series A funding round led by Artem Ventures. The roun... |
| 24.07.2023 | Singapore biotech firm Engine Biosciences raises $18m | Engine Biosciences, a Singapore- and Silicon Valley-based biotech company, has raised $18 million in a new round backed by existing investors Polaris Partners and EDBI, according to its recent filings. |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build. ClavystBio has committed US$220 million to date in investments to launch global ... |
| 28.05.2021 | Engine Biosciences Raises $43M in Series A Funding | Engine Biosciences, Singapore- and San Carlos, CA-based company deciphering complex biology to create medicines , raised $43m in Series A funding round. The round was led by Polaris Partners qith participation from new investors Invus and o... |
| 27.05.2021 | Engine Biosciences raises close to USD 42 million in Series A funding | Engine Biosciences, a Singapore- and US-based drug discovery company, has raised close to US$42 million (S$57 million) in Series A financing from a slew of investors. Led by Polaris Partner, the round was also joined by Invus, 6 Dimensions ... |
Show more